Burney Co. Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Burney Co. raised its position in shares of Pfizer Inc. (NYSE:PFE) by 262.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 143,731 shares of the biopharmaceutical company’s stock after buying an additional 104,112 shares during the period. Burney Co.’s holdings in Pfizer were worth $3,813,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Apella Capital LLC increased its holdings in shares of Pfizer by 16.7% during the fourth quarter. Apella Capital LLC now owns 21,228 shares of the biopharmaceutical company’s stock valued at $563,000 after acquiring an additional 3,035 shares in the last quarter. Park Avenue Securities LLC increased its holdings in shares of Pfizer by 11.4% during the fourth quarter. Park Avenue Securities LLC now owns 106,050 shares of the biopharmaceutical company’s stock valued at $2,814,000 after acquiring an additional 10,824 shares in the last quarter. San Luis Wealth Advisors LLC increased its holdings in shares of Pfizer by 18.0% during the fourth quarter. San Luis Wealth Advisors LLC now owns 32,175 shares of the biopharmaceutical company’s stock valued at $854,000 after acquiring an additional 4,900 shares in the last quarter. Allen Mooney & Barnes Investment Advisors LLC increased its holdings in shares of Pfizer by 14.4% during the fourth quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 25,851 shares of the biopharmaceutical company’s stock valued at $686,000 after acquiring an additional 3,256 shares in the last quarter. Finally, Rockland Trust Co. increased its holdings in shares of Pfizer by 6.2% during the fourth quarter. Rockland Trust Co. now owns 429,514 shares of the biopharmaceutical company’s stock valued at $11,395,000 after acquiring an additional 25,260 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on PFE shares. Bank of America reaffirmed a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Stock Performance

Shares of PFE stock opened at $26.25 on Thursday. The stock has a market cap of $148.76 billion, a PE ratio of 35.47, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The business has a 50-day simple moving average of $26.13 and a 200-day simple moving average of $28.03. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.17) EPS. On average, equities analysts expect that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.55%. Pfizer’s dividend payout ratio is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.